CYBRD1 | Cytochrome b reductase 1 | Predicted membrane proteins
| | | | | Expressed in all |
DAGLB | Diacylglycerol lipase, beta | Predicted membrane proteins
| | | | | Expressed in all |
DCSTAMP | Dendrocyte expressed seven transmembrane protein | Predicted membrane proteins
| | | | | Tissue enriched |
DEGS1 | Delta(4)-desaturase, sphingolipid 1 | Predicted membrane proteins
| | | | | Expressed in all |
DERL2 | Derlin 2 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
DERL3 | Derlin 3 | Plasma proteins Predicted intracellular proteins Predicted membrane proteins
| | | | | Mixed |
DPY19L2 | Dpy-19-like 2 (C. elegans) | Disease related genes Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
DUOXA1 | Dual oxidase maturation factor 1 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
DUOXA2 | Dual oxidase maturation factor 2 | Disease related genes Predicted membrane proteins
| | | | | Group enriched |
EBP | Emopamil binding protein (sterol isomerase) | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Expressed in all |
EDNRA | Endothelin receptor type A | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Mixed |
EMR1 | Egf-like module containing, mucin-like, hormone receptor-like 1 | G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
FADS1 | Fatty acid desaturase 1 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FADS2 | Fatty acid desaturase 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FADS3 | Fatty acid desaturase 3 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FADS6 | Fatty acid desaturase 6 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
FAIM2 | Fas apoptotic inhibitory molecule 2 | Predicted membrane proteins
| | | | | Tissue enriched |
FAM57A | Family with sequence similarity 57, member A | Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
FAM57B | Family with sequence similarity 57, member B | Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
FAXDC2 | Fatty acid hydroxylase domain containing 2 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
FFAR4 | Free fatty acid receptor 4 | G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
FITM2 | Fat storage-inducing transmembrane protein 2 | Predicted membrane proteins
| | | | | Expressed in all |
G6PC3 | Glucose 6 phosphatase, catalytic, 3 | Disease related genes Enzymes Potential drug targets Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
GALNT8 | Polypeptide N-acetylgalactosaminyltransferase 8 | Enzymes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
GDPD2 | Glycerophosphodiester phosphodiesterase domain containing 2 | Cytoskeleton related proteins Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
GDPD4 | Glycerophosphodiester phosphodiesterase domain containing 4 | Predicted membrane proteins
| | | | | Tissue enriched |
GNRHR | Gonadotropin-releasing hormone receptor | Disease related genes FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GPR1 | G protein-coupled receptor 1 | G-protein coupled receptors Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enhanced |
GPR137 | G protein-coupled receptor 137 | Predicted intracellular proteins Predicted membrane proteins
| | | | | Tissue enriched |
GPR143 | G protein-coupled receptor 143 | Disease related genes G-protein coupled receptors Potential drug targets Predicted membrane proteins
| | | | | Mixed |
GRINA | Glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding) | Predicted intracellular proteins Predicted membrane proteins
| | | | | Expressed in all |
HCN1 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 1 | Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
HCN3 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 3 | Plasma proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Mixed |
HCN4 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 4 | Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
HHATL | Hedgehog acyltransferase-like | Predicted membrane proteins
| | | | | Group enriched |
HRH4 | Histamine receptor H4 | G-protein coupled receptors Predicted membrane proteins
| | | | | Not detected |
HTR2A | 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enriched |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNA6 | Potassium voltage-gated channel, shaker-related subfamily, member 6 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Not detected |
KCNA7 | Potassium voltage-gated channel, shaker-related subfamily, member 7 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNF1 | Potassium voltage-gated channel, subfamily F, member 1 | Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNH1 | Potassium voltage-gated channel, subfamily H (eag-related), member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |
KCNH2 | Potassium voltage-gated channel, subfamily H (eag-related), member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH3 | Potassium voltage-gated channel, subfamily H (eag-related), member 3 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNH6 | Potassium voltage-gated channel, subfamily H (eag-related), member 6 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK15 | Potassium channel, subfamily K, member 15 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK16 | Potassium channel, subfamily K, member 16 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNK17 | Potassium channel, subfamily K, member 17 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNK3 | Potassium channel, subfamily K, member 3 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK4 | Potassium channel, subfamily K, member 4 | Predicted intracellular proteins Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enriched |